Of note, CXCR2 antagonist largely reduced tumor‐infiltrating and peripheral neutrophils, but had less effect on tumor‐infiltrating monocytes and macrophages (Figure 2C; Figure S4B–D, Supporting Information). This evidence concerns the gene CXCR2 and neoplasm.